U.S. Senator Initiates Probe into FDA's Rejection of Rare Disease Treatments

A prominent Republican senator has announced an investigation into the Food and Drug Administration's (FDA) recent decisions to deny treatments for rare diseases. Bloomberg posted on X, highlighting concerns over the agency's handling of applications for therapies aimed at addressing uncommon medical conditions. The senator's inquiry seeks to understand the rationale behind the FDA's rejections and assess whether the agency's processes are adequately supporting innovation in the healthcare sector. This investigation comes amid growing scrutiny of regulatory practices affecting drug approvals and patient access to potentially life-saving treatments.